更昔洛韦治疗儿童传染性单核细胞增多症临床分析

目的：观察更昔洛韦治疗小儿传染性单核细胞增多症的临床疗效和安全性。方法：将确诊为传染性单核细胞增多症的32例患儿随机分为治疗组16例和对照组16例,对照组给予利巴韦林10~15 mg/（kg·d）静脉滴注,每天1次,治疗组给予更昔洛韦5 mg/（kg·d）静脉滴注,每12 h 1次,两组疗程均为7~10 d,比较两组患儿临床症状消退时间、有效率和不良反应发生情况等。结果：两组发热、咽峡炎、肝脾淋巴结肿大恢复时间比较,治疗组较对照组明显缩短,差异有统计学意义（P〈0.05）;治疗组总有效率93.8%,对照组总有效率75.0%,两组比较差异有统计学意义（P〈0.05）;在治疗观察期间更昔洛韦治疗组未见明显不良反应。结论：更昔洛韦治疗小儿传染性单核细胞增多症可明显缩短热程,减轻症状,安全有效,值得推广。

Clinical Analysis of Ganciclovir in the Treatment of Children with Infectious Mononucleosis

Objective： To investigate the efficacy and safety of ganciclovir in children with infectious mononucleosis. Methods： Thirty-two cases with infectious mononucleosis were randomly divided into two groups： the treatment group （n = 16） treated with ganciclovir 5 rag/（kg · d） intravenous drip; the control group （n = 16 ） treated with ribavirin 10 ~ 15 mg/（ kg · d ） intravenous drip. The clinical symptoms, efficacy and adverse reactions were compared between the two groups. Results： The recovery length of fever, angina, liver, spleen and lymph nodes enlargements in the treatment group were shorter than those in the control group; the difference was statistically significant （P〈0.05）. The total effective rate of the treatment group was 93.0% , while of the control group it was 75.0% , the difference between the two groups was statistically significant （P〈0.05）. There were no adverse reactions observed in the group treated with ganciclovir. Conclusions： Ganciclovir is effective and safe in treating children with infectious mononucleosis.